Skip to content
No picture yet

Zejula 100 mg – DIN 02530031

Zejula is Niraparib Tosylate 100 mg (tablet), sold in Canada. It is used for fallopian tube neoplasms, ovarian neoplasms and peritoneal neoplasms. It is supplied by Glaxosmithkline Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Niraparib Tosylate 100 mg

Brand
Zejula
Strength
100 mg
Used for
Fallopian tube neoplasms, ovarian neoplasms and peritoneal neoplasms
Form
Tablet
Manufacturer
Glaxosmithkline Inc
Drug class
Poly(adp-ribose) polymerase inhibitor
Sold in
Canada
DIN
02530031

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Niraparib pills and guides

What is Niraparib used for?

Niraparib is used for fallopian tube neoplasms, ovarian neoplasms and peritoneal neoplasms.

Medicine type
Poly(adp-ribose) polymerase inhibitor
Official uses from the US prescribing label

First-Line Maintenance Treatment of HRD-Positive Advanced Ovarian Cancer

ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:

  • a deleterious or suspected deleterious BRCA mutation, and/or
  • genomic instability.

Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA.

Maintenance Treatment of Recurrent Germline BRCA-Mutated Ovarian Cancer

ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAmut) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA.

From the FDA-approved label on DailyMed (published Aug 06, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02530031.
  • It names Zejula, Niraparib Tosylate 100 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Zejula by Glaxosmithkline Inc.

In Canada: prescription only.

Ingredients

Active: Niraparib (Niraparib Tosylate)

Other Niraparib pills